Boehringer Ingelheim

Citing toxicity concerns, Boehringer Ingelheim drops short-lived IPF pact — keeping $1B+ in its pocket
Citing toxicity concerns, Boehringer Ingelheim drops short-lived IPF pact — keeping $1B+ in its pocket
Endpoints
Boehringer Ingelheim
IPF
Bridge Biotherapeutics
BBT-877
Flag link:
Boehringer, Yale trial digital tech in heart failure
Boehringer, Yale trial digital tech in heart failure
Pharmaforum
Boehringer Ingelheim
Yale
digital therapeutics
digital health
heart failure
Flag link:
Boehringer hopes schizophrenia apps will Click into place
Boehringer hopes schizophrenia apps will Click into place
EP Vantage
digital therapeutics
Boehringer Ingelheim
Click Therapeutics
schizophrenia
CT-155
Flag link:
After Novartis left, Boehringer bets up to $500M on the field of prescription smartphone app
After Novartis left, Boehringer bets up to $500M on the field of prescription smartphone app
Endpoints
Boehringer Ingelheim
digital therapeutics
Click Therapeutics
mobile apps
Novartis
Flag link:
ESC 2020 – Jardiance joins Farxiga in showing heart failure benefit
ESC 2020 – Jardiance joins Farxiga in showing heart failure benefit
EP Vantage
ESC
Eli Lilly
Boehringer Ingelheim
Farxiga
Jardiance
heart failure
AstraZeneca
Flag link:
Boehringer calls off €627M deal with GSK spinout, passing on schizophrenia drug option
Boehringer calls off €627M deal with GSK spinout, passing on schizophrenia drug option
Endpoints
Boehringer Ingelheim
GSK
schizophrenia
Autifony
AUT00206
Flag link:
Boehringer Ingelheim to Pay $379,000 to Settle Wage Discrimination Charges
Boehringer Ingelheim to Pay $379,000 to Settle Wage Discrimination Charges
BioSpace
Boehringer Ingelheim
gender discrimination
Flag link:
Boehringer and Lilly’s Jardiance Hits Mark in Decreasing Risk of Death in Heart Failure
Boehringer and Lilly’s Jardiance Hits Mark in Decreasing Risk of Death in Heart Failure
BioSpace
Boehringer Ingelheim
Eli Lilly
Jardiance
heart failure
diabetes
clinical trials
Flag link:
Boehringer Ingelheim beefs up vet portfolio with GST buyout
Boehringer Ingelheim beefs up vet portfolio with GST buyout
Endpoints
animal health
Boehringer Ingelheim
M&A
Global Stem Technology
Flag link:
Boehringer Ingelheim-backed COVID researchers identify new antibodies to fight the virus
Boehringer Ingelheim-backed COVID researchers identify new antibodies to fight the virus
Fierce Pharma
Boehringer Ingelheim
COVID-19
antivirals
antibodies
Flag link:
Boehringer creates Shanghai hub to connect with Chinese R&D groups
Boehringer creates Shanghai hub to connect with Chinese R&D groups
Fierce Biotech
Boehringer Ingelheim
China
Shanghai
R&D
Flag link:
Looking for 'external innovation,' Boehringer Ingelheim reserves $500M+ for new Shanghai hub
Looking for 'external innovation,' Boehringer Ingelheim reserves $500M+ for new Shanghai hub
Endpoints
China
Shanghai
Boehringer Ingelheim
drug manufacturing
Flag link:
Coalition of drugmakers to unveil $1B venture to pursue antibiotics
Coalition of drugmakers to unveil $1B venture to pursue antibiotics
Beckers Hospital Review
Big Pharma
drug development
antibiotics
innovation
Eli Lilly
Pfizer
Merck
Boehringer Ingelheim
Bayer
CARB-X
Flag link:
Boehringer debuts IPF songwriting contest with MLB player-turned-singer Bernie Williams
Boehringer debuts IPF songwriting contest with MLB player-turned-singer Bernie Williams
Fierce Pharma
Boehringer Ingelheim
IPF
drug marketing
Flag link:
Boehringer Ingelheim nabs new US president and CEO
Boehringer Ingelheim nabs new US president and CEO
Endpoints
Boehringer Ingelheim
Pharma CEOs
Jean-Michel Boers
Flag link:
Boehringer launches open innovation project for work-at-home scientists
Boehringer launches open innovation project for work-at-home scientists
Pharmaforum
Boehringer Ingelheim
R&D
pandemic
COVID-19
opnMe
Flag link:
Boehringer Ingelheim collaborates with CDR-Life to develop antibody fragment-based therapeutics for geographic atrophy
Boehringer Ingelheim collaborates with CDR-Life to develop antibody fragment-based therapeutics for geographic atrophy
Pharmaceutical Business Review
Boehringer Ingelheim
CDR-Life
antibody fragments
geographic atrophy
R&D
Flag link:
Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Pipeline
Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Pipeline
Xconomy
Northern Biologics
Boehringer Ingelheim
cancer immunology
Flag link:
Boehringer Ingelheim adds second AI partner in a month
Boehringer Ingelheim adds second AI partner in a month
Endpoints
Boehringer Ingelheim
artificial intelligence
BERG
Bayesian AI
biomarkers
Crohn's Disease
inflammatory bowel disease
Flag link:
The top pharma companies in social media
The top pharma companies in social media
Fierce Pharma
social media
Boehringer Ingelheim
AbbVie
GSK
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Flag link:

Pages